University of South Florida Morsani Clinical Neurophysiology

Topics

• Epilepsy research and treatment 127
• Myasthenia Gravis and Thymoma 42
• Psychosomatic Disorders and Their Treatments 41
• Amyotrophic Lateral Sclerosis Research 32
• Mitochondrial Function and Pathology 21
• EEG and Brain-Computer Interfaces 20
• Advanced Glycation End Products research 14
• Peripheral Neuropathies and Disorders 12
• Vagus Nerve Stimulation Research 12
• Autoimmune Neurological Disorders and Treatments 7
• Genetic Neurodegenerative Diseases 7
• Neurogenetic and Muscular Disorders Research 6

Most cited

1. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.

   The Lancet. Neurology · 2021 · 608 citations · Tuan Vu

2. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.

   The Lancet. Neurology · 2023 · 231 citations · Tuan Vu

3. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.

   The Lancet. Neurology · 2023 · 218 citations · Tuan Vu

4. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.

   The Lancet. Neurology · 2025 · 76 citations · Tuan Vu

5. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.

   The Lancet. Neurology · 2023 · 236 citations · Tuan Vu

6. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.